Janus Henderson Group PLC Decreases Holdings in DexCom, Inc. (NASDAQ:DXCM)

Janus Henderson Group PLC decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 6.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 521,812 shares of the medical device company's stock after selling 34,369 shares during the period. Janus Henderson Group PLC owned approximately 0.13% of DexCom worth $40,581,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Czech National Bank raised its stake in shares of DexCom by 3.7% during the fourth quarter. Czech National Bank now owns 84,689 shares of the medical device company's stock valued at $6,586,000 after acquiring an additional 3,057 shares during the last quarter. Capital Investment Advisors LLC bought a new position in DexCom during the 4th quarter valued at approximately $206,000. 180 Wealth Advisors LLC bought a new position in DexCom during the 4th quarter valued at approximately $255,000. Allen Mooney & Barnes Investment Advisors LLC purchased a new stake in DexCom in the 4th quarter worth approximately $477,000. Finally, Park Avenue Securities LLC grew its position in shares of DexCom by 13.9% in the 4th quarter. Park Avenue Securities LLC now owns 13,347 shares of the medical device company's stock worth $1,038,000 after buying an additional 1,627 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Trading Up 0.4%

Shares of DexCom stock traded up $0.39 during trading on Tuesday, hitting $87.35. The stock had a trading volume of 531,683 shares, compared to its average volume of 4,341,575. The stock has a market cap of $34.25 billion, a PE ratio of 61.11, a PEG ratio of 2.30 and a beta of 1.43. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $132.09. The firm's fifty day simple moving average is $72.33 and its 200-day simple moving average is $77.80. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the previous year, the business earned $0.32 EPS. The firm's revenue for the quarter was up 12.5% on a year-over-year basis. As a group, sell-side analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analysts Set New Price Targets

DXCM has been the topic of a number of recent research reports. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Canaccord Genuity Group increased their price objective on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Morgan Stanley increased their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research note on Friday, February 14th. Mizuho began coverage on DexCom in a report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price target for the company. Finally, Cfra Research raised shares of DexCom to a "hold" rating in a report on Friday, March 21st. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $98.11.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 13,000 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the transaction, the executive vice president now owns 105,602 shares of the company's stock, valued at approximately $7,432,268.76. This trade represents a 10.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 14,076 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the transaction, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at $22,063,918.86. This trade represents a 4.30% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 66,926 shares of company stock valued at $4,734,384. Insiders own 0.32% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.